Total Payments
$7,736
2024 Payments
$709.99
Companies
31
Transactions
408
Medicare Patients
7,652
Medicare Billing
$967,777
Payment Breakdown by Category
Food & Beverage$6,449 (83.4%)
Consulting$1,200 (15.5%)
Travel$74.90 (1.0%)
Education$12.02 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,449 | 404 | 83.4% |
| Consulting Fee | $1,200 | 1 | 15.5% |
| Travel and Lodging | $74.90 | 1 | 1.0% |
| Education | $12.02 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,893 | 45 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,019 | 63 | $0 (2024) |
| GlaxoSmithKline, LLC. | $677.43 | 41 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $515.02 | 34 | $0 (2019) |
| Lilly USA, LLC | $458.05 | 37 | $0 (2024) |
| ABBVIE INC. | $370.62 | 22 | $0 (2023) |
| Purdue Pharma L.P. | $286.06 | 14 | $0 (2018) |
| Cardiovascular Systems Inc. | $265.52 | 4 | $0 (2019) |
| PFIZER INC. | $261.11 | 23 | $0 (2021) |
| Amgen Inc. | $201.26 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $709.99 | 40 | AstraZeneca Pharmaceuticals LP ($196.79) |
| 2023 | $259.19 | 15 | GlaxoSmithKline, LLC. ($101.95) |
| 2022 | $322.82 | 19 | ABBVIE INC. ($58.61) |
| 2021 | $520.10 | 29 | Rigel Pharmaceuticals, Inc. ($124.85) |
| 2020 | $414.70 | 27 | AstraZeneca Pharmaceuticals LP ($96.55) |
| 2019 | $1,009 | 68 | AstraZeneca Pharmaceuticals LP ($248.94) |
| 2018 | $1,274 | 71 | AstraZeneca Pharmaceuticals LP ($292.16) |
| 2017 | $3,226 | 139 | Novo Nordisk Inc ($1,508) |
All Payment Transactions
408 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.01 | General |
| Category: RESPIRATORY | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $16.03 | General |
| Category: Cardio-renal | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: RESPIRATORY | ||||||
| 10/30/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.39 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Cardio-renal | ||||||
| 10/24/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 10/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $21.32 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/01/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Respiratory | ||||||
| 09/26/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: RESPIRATORY | ||||||
| 08/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: RESPIRATORY | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Respiratory | ||||||
| 08/14/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Cardio-renal | ||||||
| 08/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $21.51 | General |
| Category: RESPIRATORY | ||||||
| 07/25/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardio-renal | ||||||
| 07/24/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Diabetes | ||||||
| 07/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Cardio-renal | ||||||
| 07/03/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $6.71 | General |
| Category: RESPIRATORY | ||||||
| 06/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.98 | General |
| Category: Cardio-renal | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $37.54 | General |
| Category: Respiratory | ||||||
| 06/19/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,472 | 4,238 | $445,041 | $226,002 |
| 2022 | 25 | 1,554 | 4,078 | $379,023 | $198,406 |
| 2021 | 28 | 2,521 | 5,633 | $492,728 | $266,952 |
| 2020 | 29 | 2,105 | 5,955 | $555,049 | $276,417 |
Total Patients
7,652
Total Services
19,904
Medicare Billing
$967,777
Procedure Codes
102
All Medicare Procedures & Services
102 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 266 | 2,092 | $248,588 | $126,313 | 50.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 139 | 359 | $57,081 | $29,054 | 50.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 174 | 187 | $55,165 | $24,662 | 44.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 97 | 97 | $17,721 | $11,805 | 66.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 66 | 141 | $18,189 | $8,323 | 45.8% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 18 | 24 | $7,416 | $4,971 | 67.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 45 | $7,035 | $4,100 | 58.3% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 116 | 243 | $7,047 | $3,151 | 44.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 125 | 270 | $2,318 | $2,150 | 92.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 124 | 256 | $4,864 | $1,927 | 39.6% |
| 90682 | Influenza vaccine, quadrivalent derived from recombinant dna | Office | 2023 | 24 | 24 | $1,896 | $1,716 | 90.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 99 | 99 | $2,475 | $1,689 | 68.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 16 | $3,344 | $1,592 | 47.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 43 | 44 | $1,716 | $1,254 | 73.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 60 | 127 | $3,175 | $1,192 | 37.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 109 | $4,251 | $1,113 | 26.2% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 12 | 15 | $1,560 | $584.70 | 37.5% |
| 90686 | Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage | Office | 2023 | 12 | 12 | $420.00 | $262.80 | 62.6% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 14 | 19 | $190.00 | $74.86 | 39.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 18 | 59 | $590.00 | $67.67 | 11.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 179 | 1,766 | $192,494 | $97,199 | 50.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 150 | 398 | $63,282 | $31,523 | 49.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 125 | 139 | $29,051 | $14,518 | 50.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 89 | 218 | $28,041 | $13,734 | 49.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 109 | 109 | $18,421 | $13,606 | 73.9% |
About Harshad Patel
Harshad Patel is a Internal Medicine healthcare provider based in Rainbow City, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093770018.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Harshad Patel has received a total of $7,736 in payments from pharmaceutical and medical device companies, with $709.99 received in 2024. These payments were reported across 408 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,449).
As a Medicare-enrolled provider, Patel has provided services to 7,652 Medicare beneficiaries, totaling 19,904 services with total Medicare billing of $967,777. Data is available for 4 years (2020–2023), covering 102 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Rainbow City, AL
- Active Since 04/20/2006
- Last Updated 05/20/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1093770018
Products in Payments
- Victoza (Drug) $1,562
- TRELEGY ELLIPTA (Drug) $469.00
- FARXIGA (Drug) $438.90
- XARELTO (Drug) $305.86
- Coronary Orbital Atherectomy System (Device) $265.52
- Creon (Drug) $213.73
- JARDIANCE (Drug) $204.90
- INVOKANA (Drug) $203.14
- SYMBICORT (Drug) $192.41
- Kerendia (Drug) $175.86
- Ozempic (Drug) $172.79
- TRULICITY (Drug) $168.66
- AIRSUPRA (Drug) $164.23
- TRADJENTA (Drug) $161.70
- ELIQUIS (Drug) $152.90
- LINZESS (Drug) $143.80
- Tresiba (Drug) $135.86
- Trintellix (Drug) $131.97
- BYDUREON (Drug) $131.12
- BREO (Drug) $128.93
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.